SDC1

Syndecan-1

Score: 0.547 Price: $0.55 Low Druggability Status: active Wiki: SDC1

🧠 Neurodegeneration

HYPOTHESES

1

PAPERS

26

KG EDGES

99

DEBATES

0

3D Protein Structure

🧬 SDC1 — PDB 1QQP Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.38

Clinical Stage

Phase II

Target Class

Receptor

Safety

0.60

Druggability Analysis

Drug Development0.35

Structural Tractability0.70

Target Class0.70

Safety Profile0.60

Key Metrics

PDB Structures:

3

Known Drugs:

1

Approved:

0

In Clinical Trials:

1

Drug Pipeline (1 compounds)

1 Phase II

Druggability Rationale: SDC1 presents medium druggability (0.55 score) as a transmembrane receptor with established structural data (3 PDB structures, 1.54 Å resolution) and clinical validation through the phase 2 monoclonal antibody Indatuximab ravtansine in multiple myeloma. However, small molecule modulation of heparan sulfate interactions poses challenges due to the proteoglycan's extracellular domain complexity and the difficulty in targeting protein-glycosaminoglycan interfaces with conventional therapeutics.

Mechanism: Small molecule modulation of heparan sulfate interactions or shedding

Drug Pipeline (1 compounds)

1 Phase II

Known Drugs:

Indatuximab ravtansine (phase_2) — multiple myeloma

Structural Data:

PDB (3) ✓AlphaFold ✓Cryo-EM —

UniProt: H7C1K4

🧬 3D Protein Structure

🧬 SDC1 — PDB 1QQP Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

SDC1 is one of four syndecan family members (SDC1-4), requiring selective modulation to avoid off-target effects on related syndecans with overlapping heparan sulfate binding functions. The heparan sulfate interaction mechanism offers potential selectivity advantages over kinase inhibitors, though cross-reactivity with other heparan sulfate-binding proteins (e.g., glypicans, perlecan) remains a concern.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

1

Completed

7

Total Enrollment

860

By Phase

NA: 5 · PHASE1: 1 · PHASE2: 1 · Unknown: 1

Anger Control Training for Youth With Tourette Syndrome Completed

NA NCT00486551 n=26

Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder

Interventions: Anger control training

Sponsor: Yale University | Started: 2001-08

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Recruiting

NA NCT06909045 n=130

Deep Brain Stimulation, Parkinson Disease

Interventions: Adaptive DBS, Continue DBS

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC | Started: 2026-01-27

Expiratory Muscle Training in Patients With Parkinson's Disease Completed

PHASE1 NCT00843739 n=90

Parkinson's Disease

Interventions: EMST - Active Treatment, sham EMST

Sponsor: University of Florida | Started: 2004-01

Study of the Follow-up of Stroke Treated With Anticoagulants Completed

Unknown NCT03292575 n=441

Stroke

Interventions: Anticoagulants

Sponsor: Centre Hospitalier Universitaire Dijon | Started: 2016-01

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease Completed

NA NCT01924312 n=80

Cerebrovascular Disease, Mild Cognitive Impairment

Interventions: Heart Health Intervention

Sponsor: Gregory Jicha, 323-5550 | Started: 2013-05

Effects of Modern Board Games on Well Being in Older Adults Completed

NA NCT06306365 n=35

Executive Functions

Interventions: Modern board game-based learning

Sponsor: European University Miguel de Cervantes | Started: 2024-02-07

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol Completed

NA NCT02260167 n=25

Alzheimer's Disease, Dementia

Interventions: A mix of natural treatments and medicati

Sponsor: Practitioners Alliance Network | Started: 2014-09

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Completed

PHASE2 NCT03987295 n=33

Frontotemporal Dementia

Interventions: AL001

Sponsor: Alector Inc. | Started: 2019-09-27

Linked Hypotheses (1)

Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation0.705

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

associated with (11)

SDC1 → neurodegeneration

...and 6 more

co discussed (9)

HCRTR2 → SDC1

LOXL1-4 → SDC1

...and 4 more

Debate History (0)

No debates yet